In the final overall survival analysis, researchers pitted Lu-177-PSMA-617 (Pluvicto) against an ARPI in the second-line ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company developing first-in-class therapies for cancer ...

Following years of rotating treatments, Pepol and his family moved once more, this time to Virginia, to be close to their now ...

Dean Pepol is no stranger to prostate cancer.Prostate cancer is the second-leading type of cancer death in American men, and Pepol has experienced ...

Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have ...

In comparison to Pluvicto ® (Lu-177-PSMA-617) and the majority of radiotherapies in development for prostate cancer, which target prostate specific membrane antigen (PSMA) and are either non ...

As the Trump administration upends federal research, Mizzou aims to raise more than $1 billion to build an advanced nuclear reactor to accelerate production of key ingredients for cancer treatments.

Led by former Novartis executive Emanuele Ostuni, the startup has a prostate cancer medicine advancing into early clinical tests and is building a manufacturing network in support.

Finally, Apple is a solid dividend stock. The company has doubled its payouts over the past decade and still has a modest ...

Discover Piper Sandler's latest biotech oncology picks, ratings, and price targets. Gain expert insights on CGON, BCAX, DAWN, ...

Bruce Power first began commercially producing Lutetium-177 in 2022, following the construction of an isotope production system at the plant's Unit 7 reactor, making it the world's first commercial ...

Donald Trump has branded masked protesters in public demonstrations as terrorists, while the ICE brigands wear required face ...